Directed evolution of prenylated FMN-dependent Fdc supports efficient in vivo isobutene production by Saaret, Annica et al.
Open Access This file is licensed under a Creative Commons Attribution 4.0 
International License, which permits use, sharing, adaptation, distribution and 
reproduction in any medium or format, as long as you give appropriate credit to 
the original author(s) and the source, provide a link to the Creative Commons license, and indicate if 
changes were made. In the cases where the authors are anonymous, such as is the case for the reports of 
anonymous peer reviewers, author attribution should be to 'Anonymous Referee' followed by a clear 
attribution to the source work.  The images or other third party material in this file are included in the 
article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is 
not included in the article’s Creative Commons license and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright 
holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. 
Peer Review File
Directed evolution of prenylated FMN-dependent Fdc 
supports efficient in vivo isobutene production
REVIEWER COMMENTS 
Reviewer #1 (Remarks to the Author): 
The manuscript “Directed evolution of prFMN-dependent Fdc supports efficient in vivo isobutene 
production” by Saaret A. et al. is the latest report from the research group that has discovered prFMN 
for the first time as a novel flavin coenzyme. The authors performed directed evolution of ferulic acid 
decarboxylase from a fungus Trichoderma atroviride (TaFdc), by in vivo enzyme screening on E. coli 
system that allows the selection of TaFdc from 15 homologs and following four rounds of mutagenesis, 
while details of the process are not described. The resulting mutant TaFdcV efficiently catalyzes 
decarboxylation of 3-methylcrotonic acid with much higher activity than that of wild type TaFdc, losing 
activity toward cinnamic acid, a good substrate for the wild type. This substrate specificity was 
explained by the comparison of the crystal structures of the mutant and wild type TaFdc, and the 
change in substrate specificity by mutagenesis was reproduced with homologous Fdc from Aspergillus 
niger. Moreover, the analyses of the cycloadducts between the cofactor prFMN and 
substrate/inhibitor/intermediate revealed the limit of prFMN-dependent decarboxylase as for the 
structure of substrates. The fact that Fdc can catalyze decarboxylation of 3-methylcrotonic acid but 
cannot that of crotonic acid suggested that the rate-limiting cycloelimination step proceeds via cationic 
(or radical) mechanism. This hypothesis was supported in a clear way by computational study with 
DFT calculations based on TaFdc structures. 
The authors made an excellent job to create valuable mutant enzymes for future isobutene bio-
production. They also made important discoveries about the catalytic mechanism of prFMN-dependent 
decarboxylase. All the data in the manuscript look very sound and persuasive. The reviewer only 
requires minor modification of the manuscript as listed below: 
1) In the title, the authors should use not abbreviations but common words. An example of an 
appropriate title is “Directed evolution of prenylated FMN-dependent ferulic acid decarboxylase 
supports efficient in vivo isobutene production.” 
2) The description “conjugated acrylic acid” seems redundant because acrylic acid itself has 
conjugated C=O and C=C double bonds. Similarly, “non-conjugated acrylic acid” is unacceptable. The 
reviewer recommends the use of “acrylic acid with (or without) extended conjugation” instead. 
3) At the first appearance, the name of microorganism should not be abbreviated, like A. niger in page 
2 and T. atroviride in page 4. 
4) In page 2: “Following CO2 for E282 exchange,” should be “Following the exchange of CO2 with 
E282,”. 
5) In page 4, the authors describe that “the equivalent mutation (to TaFdcV) supported significant 
increase in isobutene production when introduced in four other Fdc homologues”. This data should be 
added as supplementary information. 
6) The way of directed mutagenesis should be described in more detail. Why and how saturation 
mutagenesis was performed in the 1st and 3rd rounds? How many mutants were screened in the 2nd 
and 4th rounds to select the mutants? If it is a long story, please add it as supplementary information. 
7) In page 5, line 5: MS-ESI > ESI-MS 
8) In page 5, line 16: no long-lived > non-long lived 
9) In page 6, line 9: where > were 
10) In page 6: Was “product extraction for pentenoic and hexenoic acid substrates” performed in a 
similar way with the extraction of cycloadduct, which is described in the Methods section? The 
experimental methods for the various analyses using pentenoic and hexenoic acid should be described 
in detail as supplementary information. 
11) In page 7: “Butynoic acid” should be “2-butynoic acid” for clarity. 
12) Throughout the manuscript: The microorganism name in the abbreviations such as “Ta” in TaFdc 
is italicized in some parts in the manuscript but not italicized in other parts. Please unify them. 
13) In page 12: “An unsaturated acrylic acid” should be “an α,β-unsaturated carboxylic acid” or just 
“an acrylic acid moiety” because acrylic acid is originally unsaturated. 
14) In the legend of Figure 6: “DFT optimized Int3 to product transition states” > “DFT optimized 
transition states between Int3 and product” 
15) In pages 14 and 16: How was the headspace gas sampling performed? Were deep well plates 
sealed throughout reaction? If so, what was used for sealing? Please describe in the Methods section. 
16) In page 15: Although the authors described “the resultant yellow solid was added to apo-Fdc (A. 
niger)”, the apo-Fdc used is considered to be TaFdcV from Table 1 and the legend of Figure 3. In 
addition, please describe how the apo-TaFdcV was prepared. 
17) In page 16, line 8: molecular placement > molecular replacement 
18) In Figure S1: Panels H, I, and J are not referred in the main text. Can they be removed? 
19) Figure S4 is referred in the main text faster than S2 and S3. Please change the numberings in 
good order. 
Reviewer #2 (Remarks to the Author): 
In this excellent manuscript, the Authors describe their successful efforts to develop a mutant of 
ferulic acid decarboxylase (Fdc) that is able to produce isobutene from 3-methylcrotonic acid. Fdc is by 
now widely known as the prototype of the enzymes that use prenylated flavins to afford the 
decarboxylation of highly conjugated substrates. This work now shows that Fdc enzymes can also 
work on non-aromatic/non-conjugated substrates such 3-methylcrotonic acid. Curiously, the Authors 
found that a substituent on the 3 position is essential for catalysis. Rather than being a substrate, 
crotonic acid is indeed found to be an inhibitor by forming a stable adduct with the prenylated flavin. 
DFT calculations indicate that the 3-methyl group creates the proper charge distribution and 
separation on the intermediate atoms as requested for intermediate decay and concomitant release of 
the decarboxylated product. This is very good work with an impact in the field of biocatalysis as well 
as in basic enzymology. Isobutene is a valuable compound and a biocatalytic route for its production is 
much needed. At the same time, this work provides considerable insight into the prenylated-favins 
and their reactivities, demonstrating that their substrate scopes can be considerably expanded by 
mutagenesis and protein discovery through genome mining. However, some limitations are posed by 
the necessity to avoid formation of “too stable dead-end” covalent intermediates. 
The manuscript is very well written. The Authors employed several analytical, enzymological, and 
structural techniques to support their conclusions. I have a few comments, mainly about a few points 
that should be clarified. 
-The Authors mention the detrimental effect of the histidine-tag on the activities. Can they elaborate 
on this observation? Any hypothesis? Here, I am actually confused because Figure S3 reports the 
conversions measured with the His-tagged proteins. The data for the untagged proteins should be 
shown as well. Overall, this point must be clarified. 
-The structural superposition of Figure 2A should be shown in two orientations to allow the reader to 
fully appreciate the amino acid replacements and associated minor structural changes. 
-The text of page 10 suddenly mentions the TaFdcI and TaFdcII variants without any previous 
description. 
-Would it be possible to include a supplementary or main text picture showing the binding of the 
substrates in the active site as it can be inferred by simple docking and previous structural work? The 
reader would like to see how 3-methylcrotonic acid and ferulic acid are known and/or expected to 
interact with the mutagenized side chains. 
Andrea Mattevi 
Reviewer #3 (Remarks to the Author): 
General comments: 
The manuscript by Saaret et al., is a well written paper on a modified mevalonate pathway using an 
evolved ferulic acid decarboxylase enzyme. This enzyme catalyzes a reversible non-oxidative 
decarboxylation of 3-methylcrotonic acid to isobutene. Not only does this work provide another 
pathway for isobutene production that is potentially more economical, significant work was performed 
on enzyme structure and function that significantly advances our understanding of the enzyme 
kinetics. The only major comment that I have does not deter from the significance of the manuscript. 
It would be nice in the results and discussion to have a more direct comparison to the previous 
literature. Currently, there is no way for me to compare if this enzyme is capable of producing higher 
titers faster than the M3K or MVD enzymes. In this respect it would be good to normalize the 
production per cell per time. It would also be helpful to switch Figure 5 for Figure S3 and have the text 
refer to the fold increase. 
Specific comments: 
- Spell out genus name the first time it is used then abbreviate. 
- Please add a few more details on the GC- i.e. column, standards. Was this paired with a mass spec? 
- Please add the organism for each enzyme in Table S1. 
Brandon Briggs
Point-by-point response to authors comments: 
Reviewer #1 (Remarks to the Author): 
The manuscript “Directed evolution of prFMN-dependent Fdc supports efficient in vivo isobutene production” 
by Saaret A. et al. is the latest report from the research group that has discovered prFMN for the first time as 
a novel flavin coenzyme. The authors performed directed evolution of ferulic acid decarboxylase from a 
fungus Trichoderma atroviride (TaFdc), by in vivo enzyme screening on E. coli system that allows the 
selection of TaFdc from 15 homologs and following four rounds of mutagenesis, while details of the process 
are not described. The resulting mutant TaFdcV efficiently catalyzes decarboxylation of 3-methylcrotonic acid 
with much higher activity than that of wild type TaFdc, losing activity toward cinnamic acid, a good substrate 
for the wild type. This substrate specificity was explained by the comparison of the crystal structures of the 
mutant and wild type TaFdc, and the change in substrate specificity by mutagenesis was reproduced with 
homologous Fdc from Aspergillus niger. Moreover, the analyses of the cycloadducts between the cofactor 
prFMN and substrate/inhibitor/intermediate revealed the limit of prFMN-dependent decarboxylase as for the 
structure of substrates. The fact that Fdc can catalyze decarboxylation of 3-methylcrotonic acid but cannot 
that of crotonic acid suggested that the rate-limiting cycloelimination step proceeds via cationic (or radical) 
mechanism. This hypothesis was supported in a clear way by computational study with DFT calculations 
based on TaFdc structures. 
The authors made an excellent job to create valuable mutant enzymes for future isobutene bio-production. 
They also made important discoveries about the catalytic mechanism of prFMN-dependent decarboxylase. 
All the data in the manuscript look very sound and persuasive. The reviewer only requires minor modification 
of the manuscript as listed below: 
1) In the title, the authors should use not abbreviations but common words. An example of an appropriate 
title is “Directed evolution of prenylated FMN-dependent ferulic acid decarboxylase supports efficient in vivo 
isobutene production.”  
This has now been fixed
2) The description “conjugated acrylic acid” seems redundant because acrylic acid itself has conjugated C=O 
and C=C double bonds. Similarly, “non-conjugated acrylic acid” is unacceptable. The reviewer recommends 
the use of “acrylic acid with (or without) extended conjugation” instead. This has now been fixed
3) At the first appearance, the name of microorganism should not be abbreviated, like A. niger in page 2 and 
T. atroviride in page 4.  
This has now been fixed
4) In page 2: “Following CO2 for E282 exchange,” should be “Following the exchange of CO2 with E282,”.  
This has now been fixed
5) In page 4, the authors describe that “the equivalent mutation (to TaFdcV) supported significant increase in 
isobutene production when introduced in four other Fdc homologues”. This data should be added as 
supplementary information. We have removed this sentence from the manuscript.
6) The way of directed mutagenesis should be described in more detail. Why and how saturation mutagenesis 
was performed in the 1st and 3rd rounds? How many mutants were screened in the 2nd and 4th rounds to 
select the mutants? If it is a long story, please add it as supplementary information. Figure S1 added to 
supplementary material. 
7) In page 5, line 5: MS-ESI > ESI-MS This has now been fixed
8) In page 5, line 16: no long-lived > non-long lived We have altered the sentence to improve clarity 
9) In page 6, line 9: where > were This has now been fixed
10) In page 6: Was “product extraction for pentenoic and hexenoic acid substrates” performed in a similar way 
with the extraction of cycloadduct, which is described in the Methods section? The experimental methods for 
the various analyses using pentenoic and hexenoic acid should be described in detail as supplementary 
information.  Pentenoic and hexenoic acid adduct were not extracted but the turnover was analysed by MS, 
we clarified the text. 
11) In page 7: “Butynoic acid” should be “2-butynoic acid” for clarity. This has now been fixed
12) Throughout the manuscript: The microorganism name in the abbreviations such as “Ta” in TaFdc is 
italicized in some parts in the manuscript but not italicized in other parts. Please unify them. This has now 
been fixed
13) In page 12: “An unsaturated acrylic acid” should be “an α,β-unsaturated carboxylic acid” or just “an acrylic 
acid moiety” because acrylic acid is originally unsaturated. This has now been fixed
14) In the legend of Figure 6: “DFT optimized Int3 to product transition states” > “DFT optimized transition 
states between Int3 and product” This has now been fixed
15) In pages 14 and 16: How was the headspace gas sampling performed? Were deep well plates sealed 
throughout reaction? If so, what was used for sealing? Please describe in the Methods section. We have added 
a line to methods section to provide further details.
16) In page 15: Although the authors described “the resultant yellow solid was added to apo-Fdc (A. niger)”, 
the apo-Fdc used is considered to be TaFdcV from Table 1 and the legend of Figure 3. In addition, please 
describe how the apo-TaFdcV was prepared. This has now been fixed
17) In page 16, line 8: molecular placement > molecular replacement This has now been fixed
18) In Figure S1: Panels H, I, and J are not referred in the main text. Can they be removed? Added two 
sentences about light-sensitivity in text referring to those figures.
19) Figure S4 is referred in the main text faster than S2 and S3. Please change the numberings in good order. 
Supplementary figures reordered according to occurrence order in text 
Reviewer #2 (Remarks to the Author): 
In this excellent manuscript, the Authors describe their successful efforts to develop a mutant of ferulic acid 
decarboxylase (Fdc) that is able to produce isobutene from 3-methylcrotonic acid. Fdc is by now widely 
known as the prototype of the enzymes that use prenylated flavins to afford the decarboxylation of highly 
conjugated substrates. This work now shows that Fdc enzymes can also work on non-aromatic/non-
conjugated substrates such 3-methylcrotonic acid. Curiously, the Authors found that a substituent on the 3 
position is essential for catalysis. Rather than being a substrate, crotonic acid is indeed found to be an 
inhibitor by forming a stable adduct with the prenylated flavin. DFT calculations indicate that the 3-methyl 
group creates the proper charge distribution and separation on the intermediate atoms as requested for 
intermediate decay and concomitant release of the decarboxylated product. This is very good work with an 
impact in the field of biocatalysis as well as in basic enzymology. Isobutene is a valuable compound and a 
biocatalytic route for its production is much needed. At the same time, this work provides considerable 
insight into the prenylated-favins and their reactivities, demonstrating that their substrate scopes can be 
considerably expanded by mutagenesis and protein discovery through genome mining. However, some 
limitations are posed by the necessity to avoid formation of “too stable dead-end” covalent intermediates. 
The manuscript is very well written. The Authors employed several analytical, enzymological, and structural 
techniques to support their conclusions. I have a few comments, mainly about a few points that should be 
clarified. 
-The Authors mention the detrimental effect of the histidine-tag on the activities. Can they elaborate on this 
observation? Any hypothesis? Here, I am actually confused because Figure S3 reports the conversions 
measured with the His-tagged proteins. The data for the untagged proteins should be shown as well. Overall, 
this point must be clarified. We have clarified this with figure S7.
-The structural superposition of Figure 2A should be shown in two orientations to allow the reader to fully 
appreciate the amino acid replacements and associated minor structural changes. We have added another 
view. 
-The text of page 10 suddenly mentions the TaFdcI and TaFdcII variants without any previous description. We 
have added an additional sentence. 
-Would it be possible to include a supplementary or main text picture showing the binding of the substrates in 
the active site as it can be inferred by simple docking and previous structural work? The reader would like to 
see how 3-methylcrotonic acid and ferulic acid are known and/or expected to interact with the mutagenized 
side chains. We have modelled crotonic and 3-methylcrotonic, and added an overlay with alpha-
fluorocinnamic (Figure S5). 
Andrea Mattevi 
Reviewer #3 (Remarks to the Author): 
General comments: 
The manuscript by Saaret et al., is a well written paper on a modified mevalonate pathway using an evolved 
ferulic acid decarboxylase enzyme. This enzyme catalyzes a reversible non-oxidative decarboxylation of 3-
methylcrotonic acid to isobutene. Not only does this work provide another pathway for isobutene production 
that is potentially more economical, significant work was performed on enzyme structure and function that 
significantly advances our understanding of the enzyme kinetics. The only major comment that I have does 
not deter from the significance of the manuscript. It would be nice in the results and discussion to have a more 
direct comparison to the previous literature. Currently, there is no way for me to compare if this enzyme is 
capable of producing higher titers faster than the M3K or MVD enzymes. In this respect it would be good to 
normalize the production per cell per time. It would also be helpful to switch Figure 5 for Figure S3 and have 
the text refer to the 
fold increase. 
We have performed additional experiments and described these in the text and accompanying figure S8. 
Specific comments: 
- Spell out genus name the first time it is used then abbreviate. This has now been fixed
- Please add a few more details on the GC- i.e. column, standards. Was this paired with a mass spec? We have 
added some details to the methods sections.
- Please add the organism for each enzyme in Table S1. This has now been fixed
Brandon Briggs
REVIEWERS' COMMENTS 
Reviewer #1 (Remarks to the Author): 
I am totally satisfied with the revision made by the authors. 
Hisashi Hemmi 
Reviewer #2 (Remarks to the Author): 
The Authors have further improved the manuscript by addressing the comments raised by the 
Reviewers. Excellent work. 
Andrea Mattevi 
Reviewer #3 (Remarks to the Author): 
All previous comments have been more than adequately addressed. The additional experimentation is 
greatly appreciated and goes beyond what I was previously suggesting to compare rates from the 
other enzymes.
